Regulation & Compliance

Renewbrook Energy acquires PosiGen's distressed solar assets, promising stability for thousands of customers left in limbo after PosiGen's bankruptcy.

A Korean firm says it can cure 34 diseases using cells from cloned embryos, walking a fine line between a medical breakthrough and a bioethical taboo.

ZEISS launches Collaborative Care, a cloud-based solution to connect optometrists and ophthalmologists, streamlining referrals and data sharing for better care.

Bitcoin miner Abits Group raises needed cash in a dilutive offering, sending its stock plunging and shining a spotlight on its controversial dealmaker.

Argentina's Entre Ríos province launches a cash offer to buy back 2028 notes, funded by a new bond, aiming to ease debt and boost investment.

Most hospitals have static defenses ill-equipped for modern threats. A new, free framework offers a clinically-informed path to a dynamic Zero Trust posture.

Amid financial headwinds, CISO Global appoints a new EVP to accelerate AI innovation, enhance operational efficiency, and gain a competitive edge.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.

As cardiovascular disease affects nearly half of US adults, experts are urging a shift to existing, life-saving therapies that are widely ignored.

Verrica Pharmaceuticals heads to a key investor conference with strong YCANTH sales, a promising pipeline for warts and skin cancer, and high expectations.

With key investor conferences looming, Phathom Pharmaceuticals is set to showcase strong VOQUEZNA sales and a clear path to 2026 profitability.

The Biocodex Microbiota Foundation opens its 10th annual grant, committing a total of half a million dollars to shape the future of U.S. gut health science.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

A landmark FDA approval for Bracco's VUEWAY allows high-quality MRI scans in neonates with half the standard gadolinium dose, easing safety concerns.

With its lead CAR-T therapy, Descartes-08, in late-stage trials, Cartesian Therapeutics is set to update investors on its pioneering work in autoimmune disease.

With a soaring stock, $300M in new funding, and strong clinical data, Monte Rosa is set to showcase its novel disease-fighting drug platform.

A 94% surge in water damage claims reveals a growing crisis, yet a new survey shows over half of Canadians plan no action to protect their homes.

A new partnership uses AI to slash localization costs, bringing a flood of previously unavailable TV shows to European viewers on free streaming channels.

AI legal service provider DocLegal.ai issues a cease-and-desist to a confusingly similar domain, highlighting growing brand protection risks in tech.

At EuroShop 2026, Hanshow unveils AI-powered shelves and smart carts designed to create a 'digital twin' of physical stores, promising a new era of efficiency.